{"timestamp": "2026-01-22T18:32:56.942726", "question": "{\"CASE_CORE\":{\"ADJUVANT_TREATMENT\":{\"cycles_or_courses\":\"6\",\"given\":\"Yes\",\"regimens\":[\"TP\"]},\"BIOMARKERS\":{\"AFP\":\"Unknown\",\"CA125\":\"Unknown\",\"HER2\":\"Unknown\",\"MSI\":\"Unknown\",\"PDL1_CPS\":\"Unknown\",\"TMB\":\"Unknown\"},\"BRCA1\":\"Unknown\",\"BRCA2\":\"Unknown\",\"CURRENT_STATUS\":\"On maintenance niraparib; ECOG 1; recent imaging without pelvic recurrence.\",\"DIAGNOSIS\":{\"components\":[\"Adenocarcinoma\",\"High-grade serous carcinoma\"],\"histology\":\"High-grade serous carcinoma\",\"laterality\":\"Bilateral\",\"primary\":\"Ovarian cancer\",\"site\":\"Ovary\"},\"ECOG\":\"1\",\"GENOMICS\":{\"HRD_STATUS\":{\"method\":\"Unknown\",\"result\":\"Positive\",\"score\":\"Unknown\"},\"alterations\":[],\"testing_date\":\"Unknown\",\"testing_performed\":\"Yes\",\"testing_platform\":\"Unknown\"},\"HRD\":\"Positive\",\"INITIAL_TREATMENT\":\"Yes\",\"LINE_OF_THERAPY\":[{\"concurrent_bevacizumab\":\"No\",\"cycles_completed\":\"1\",\"cycles_planned\":\"Unknown\",\"discontinuation\":{\"detail\":\"Switched to TP chemotherapy\",\"reason\":\"Other\"},\"end_date\":\"2021-09-07\",\"in_clinical_trial\":\"No\",\"intent\":\"First_line\",\"line\":\"1L\",\"pfs_days\":\"41\",\"regimen\":\"顺铂50mg腹腔化疗\",\"response_assessment\":{\"best_response\":\"Unknown\",\"ca125_response\":\"Unknown\",\"response_criteria\":\"Unknown\",\"response_date\":\"Unknown\"},\"start_date\":\"2021-09-06\"},{\"concurrent_bevacizumab\":\"No\",\"cycles_completed\":\"6\",\"cycles_planned\":\"6\",\"discontinuation\":{\"detail\":\"Completed 6 cycles\",\"reason\":\"Completed\"},\"end_date\":\"2022-03-22\",\"in_clinical_trial\":\"No\",\"intent\":\"First_line\",\"line\":\"1L\",\"pfs_days\":\"Unknown\",\"regimen\":\"TP\",\"response_assessment\":{\"best_response\":\"Unknown\",\"ca125_response\":\"Unknown\",\"response_criteria\":\"Unknown\",\"response_date\":\"Unknown\"},\"start_date\":\"2021-10-18\"},{\"concurrent_bevacizumab\":\"No\",\"cycles_completed\":\"Unknown\",\"cycles_planned\":\"Unknown\",\"discontinuation\":{\"detail\":\"Temporarily stopped due to adverse reactions and low platelets; restarted 2022-05-23; held 3 weeks around hernia repair; currently continuing\",\"reason\":\"Other\"},\"end_date\":\"Unknown\",\"in_clinical_trial\":\"No\",\"intent\":\"Maintenance\",\"line\":\"1L\",\"pfs_days\":\"Unknown\",\"regimen\":\"尼拉帕利\",\"response_assessment\":{\"best_response\":\"Unknown\",\"ca125_response\":\"Unknown\",\"response_criteria\":\"Unknown\",\"response_date\":\"Unknown\"},\"start_date\":\"2022-04-Unknown\"}],\"MAINTENANCE\":\"Yes\",\"MAINTENANCE_DETAIL\":{\"end_date\":\"Unknown\",\"given\":\"Yes\",\"regimens\":[\"尼拉帕利\"],\"start_date\":\"2022-04-Unknown\"},\"NEOADJUVANT\":\"Unknown\",\"PFI_days\":\"Unknown\",\"PLATINUM_HISTORY\":[{\"PFI_days\":\"Unknown\",\"end_date\":\"2022-03-22\",\"evidence\":\"TP chemotherapy 6 cycles after primary surgery; no explicit relapse documented.\",\"evidence_type\":\"Unknown\",\"first_relapse_date\":\"Unknown\",\"line\":\"1L\",\"start_date\":\"2021-10-18\",\"status\":\"Unknown\"}],\"PLATINUM_PFI_CURRENT\":\"Unknown\",\"PLATINUM_STATUS\":\"Unknown\",\"PLATINUM_STATUS_CURRENT\":\"Unknown\",\"RELAPSE\":\"No\",\"RELAPSE_DATE\":{\"date\":\"Unknown\",\"evidence\":\"No relapse; pelvic MRI 2022-10-25 showed no abnormal soft tissue in pelvis.\",\"type\":\"Unknown\"},\"SCENE\":\"Maintenance_surveillance_followup\",\"STAGE\":{\"stage_basis\":\"Unknown\",\"stage_system\":\"Unknown\",\"stage_text\":\"Unknown\"},\"SURGERY_DONE\":{\"date\":\"2021-08-26\",\"performed\":\"Yes\",\"procedure\":\"Radical hysterectomy with bilateral salpingo-oophorectomy, pelvic mass resection, partial rectosigmoid resection, sigmoid colostomy, omentectomy, pelvic lymphadenectomy, appendectomy, paraaortic lymphadenectomy\"},\"TIMELINE\":{\"constraints\":{\"max_events\":30,\"min_events\":3,\"must_include\":[\"first diagnostic imaging or pathology confirmation (if available)\"],\"ordering_rules\":{\"prioritize_last_event\":true}},\"events\":[{\"date\":\"2021-08-26\",\"description\":\"Primary cytoreductive surgery including radical hysterectomy, bilateral salpingo-oophorectomy, bowel resection, omentectomy, lymphadenectomy, colostomy, appendectomy\",\"event_type\":\"Surgery\",\"key_result\":\"Multiple peritoneal sites and 6/24 lymph nodes positive for carcinoma\",\"regimen_or_test\":\"Surgery\"},{\"date\":\"2021-08-26\",\"description\":\"Pathology confirmed high-grade serous carcinoma of bilateral ovaries with widespread peritoneal involvement and nodal metastases\",\"event_type\":\"Diagnosis\",\"key_result\":\"High-grade serous carcinoma, bilateral ovaries; 6/24 lymph nodes positive\",\"regimen_or_test\":\"Pathology\"},{\"date\":\"2021-09-06\",\"description\":\"Intraperitoneal chemotherapy with cisplatin 50mg\",\"event_type\":\"Chemo\",\"key_result\":\"Completed over 2021-09-06 and 2021-09-07\",\"regimen_or_test\":\"顺铂50mg腹腔化疗\"},{\"date\":\"2021-10-18\",\"description\":\"Started TP chemotherapy, planned 6 cycles\",\"event_type\":\"Chemo\",\"key_result\":\"Completed 6 cycles, last on 2022-03-22\",\"regimen_or_test\":\"TP\"},{\"date\":\"2022-03-22\",\"description\":\"Last cycle of TP chemotherapy\",\"event_type\":\"Chemo\",\"key_result\":\"Adjuvant chemotherapy completed\",\"regimen_or_test\":\"TP\"},{\"date\":\"2022-04-18\",\"description\":\"Complete blood count showing thrombocytopenia\",\"event_type\":\"Lab\",\"key_result\":\"PLT:33\",\"regimen_or_test\":\"Blood routine\"},{\"date\":\"2022-04-26\",\"description\":\"Stopped niraparib due to strong adverse reactions\",\"event_type\":\"Other\",\"key_result\":\"Maintenance paused\",\"regimen_or_test\":\"尼拉帕利\"},{\"date\":\"2022-05-23\",\"description\":\"Restarted niraparib 1# qd\",\"event_type\":\"Chemo\",\"key_result\":\"Maintenance resumed\",\"regimen_or_test\":\"尼拉帕利\"},{\"date\":\"2022-06-24\",\"description\":\"Abdominal wall hernia repair at Zhongshan Hospital\",\"event_type\":\"Surgery\",\"key_result\":\"Niraparib held for 3 weeks around surgery\",\"regimen_or_test\":\"Surgery\"},{\"date\":\"2022-09-27\",\"description\":\"CT chest/abdomen showing small bilateral pleural effusions improved; pulmonary AV fistula and nodules similar to prior\",\"event_type\":\"Imaging\",\"key_result\":\"No new malignant findings reported; abdominal details deferred\",\"regimen_or_test\":\"CT\"},{\"date\":\"2022-10-08\",\"description\":\"CT showing liver segment VII hemangioma and left renal cyst, stable\",\"event_type\":\"Imaging\",\"key_result\":\"No new findings; chest to correlate with other exams\",\"regimen_or_test\":\"CT\"},{\"date\":\"2022-10-25\",\"description\":\"Pelvic MRI after ovarian cancer surgery\",\"event_type\":\"Imaging\",\"key_result\":\"No abnormal soft tissue in pelvis; follow-up recommended\",\"regimen_or_test\":\"MR\"},{\"date\":\"2022-12-30\",\"description\":\"Zhongshan Hospital evaluation: incisional hernia, low-density lesion in right liver lobe\",\"event_type\":\"Imaging\",\"key_result\":\"Blood count and liver/kidney function generally acceptable\",\"regimen_or_test\":\"Imaging\"},{\"date\":\"2023-01-09\",\"description\":\"Recent blood routine showed platelet count 34 (year not fully specified)\",\"event_type\":\"Lab\",\"key_result\":\"PLT:34 (interpreted from 'PLT:342022.5.23起恢复', year unclear)\",\"regimen_or_test\":\"Blood routine\"}]},\"VISIT_DATE\":\"2023-01-09\",\"first_relapse_date\":\"Unknown\",\"last_platinum_end_date\":\"2022-03-22\"},\"CLINICAL_TRIALS\":[],\"LAB_TRENDS\":{\"labs\":[{\"analyte\":\"Other\",\"history\":[{\"date\":\"2022-04-18\",\"flag\":\"↓\",\"value\":\"PLT:33\"}],\"latest\":{\"date\":\"2022-04-18\",\"flag\":\"↓\",\"value\":\"PLT:33\"},\"reference_range\":\"Unknown\",\"unit\":\"Unknown\"}],\"milestones\":[{\"date\":\"2021-08-26\",\"description\":\"Primary debulking surgery for ovarian cancer\",\"type\":\"Surgery\"},{\"date\":\"2021-10-18\",\"description\":\"Started TP chemotherapy\",\"type\":\"ChemoStart\"},{\"date\":\"2022-03-22\",\"description\":\"Completed TP chemotherapy\",\"type\":\"ChemoEnd\"},{\"date\":\"2022-04-18\",\"description\":\"Thrombocytopenia (PLT 33) on blood routine\",\"type\":\"Other\"}]},\"MED_ONC\":{\"current_regimen\":{\"cycle_info\":\"Continuous oral maintenance; temporarily stopped 2022-04-26 and around 2022-06-24 surgery; currently continuing\",\"last_admin_date\":\"Unknown\",\"name\":\"尼拉帕利\"},\"genetic_testing\":{\"germline\":[],\"somatic\":[\"HRD\"]},\"monitoring_points\":[{\"drug_or_class\":\"尼拉帕利\",\"monitoring\":[\"Monitor platelet count due to prior thrombocytopenia\"]}],\"planned_next_regimen\":\"Unknown\",\"prior_systemic_therapies\":[\"顺铂50mg腹腔化疗\",\"TP\"]},\"NUC_MED\":{\"studies\":[]},\"PATHOLOGY\":{\"specimens\":[{\"components\":[\"High-grade serous carcinoma\",\"Myometrial leiomyomas\",\"Chronic cervicitis\"],\"date\":\"2021-08-26\",\"diagnosis\":\"Adenocarcinoma consistent with high-grade serous carcinoma\",\"grade\":\"High-grade\",\"ihc\":[],\"involvement_sites\":[\"Left ovary\",\"Right ovary\",\"Left fallopian tube\",\"Right fallopian tube\",\"Uterine myometrium\",\"Pelvic and abdominal peritoneum\",\"Partial rectosigmoid colon from serosa to superficial muscle\",\"Omentum\",\"Left paracolic gutter peritoneum\",\"Small bowel mesentery\",\"Sigmoid mesentery\",\"Appendiceal serosa\",\"Pelvic lymph nodes\",\"Para-aortic and mesenteric lymph nodes (some positive)\"],\"laterality\":\"Bilateral ovarian involvement\",\"molecular\":[{\"result\":\"Positive\",\"test\":\"HRD\"}],\"raw_text\":\"术后病理：标本类型:扩大子宫+双附件+巨大盆块+部分直乙结肠+盆腹腔多病灶肿瘤大小:左侧：3.5×2×1.5cm；右侧：6×5.5×4.5cm肿瘤侧别:双侧病理类型:腺癌，结合免疫组化结果（I2021-07819），符合高级别浆液性癌。其他部位情况:左输卵管:见癌累及右输卵管:见癌累及子宫内膜:萎缩改变宫颈:慢性炎子宫肌层:见癌累及；肌壁间平滑肌瘤（多枚，直径0.5-2cm）盆腹腔多部位病灶:（部分直乙结肠）见癌累及，自浆膜层浸润至浅肌层，肠管两切缘未见癌累及。（大网膜、大网膜及盆腔肿块、左侧结肠旁沟腹膜、小肠系膜肿瘤、乙状结肠系膜肿瘤）见癌累及.（阑尾及周围肿块） 浆膜层见癌累及。其他:送检淋巴结（6/24）见癌转移，其中：左盆腔淋巴结（1/4）；右盆腔淋巴结（3/8）；腹主肠系膜下方淋巴结（1/4）； 肠系膜下动脉上方淋巴结（1/2）；腹主动脉旁淋巴结（0/6）。\",\"sample_type\":\"Surgical resection\",\"site\":\"Uterus, bilateral adnexa, pelvic mass, rectosigmoid colon, peritoneum, omentum, appendix, lymph nodes\",\"tumor_size\":\"Left ovary 3.5×2×1.5cm; right ovary 6×5.5×4.5cm\",\"uncertainty_or_missing\":[\"FIGO stage not provided\",\"IHC panel details not provided\"]}]},\"RADIOLOGY\":{\"next_imaging_plan\":{\"modality\":\"Unknown\",\"timing\":\"Unknown\"},\"studies\":[{\"anatomic_sites\":[\"Lung\",\"Pleura\",\"Chest\"],\"date\":\"2022-09-27\",\"findings\":[\"Right upper lung arteriovenous fistula similar to prior\",\"Right upper lung apical segment small nodule similar to prior\",\"Left upper lung scattered tiny nodules\",\"Small bilateral pleural effusions decreased compared with prior\",\"Scattered chronic inflammatory and fibrotic changes in lungs\",\"Atelectasis improved\",\"Nodule at right cardiophrenic angle less apparent\"],\"impression\":\"Pulmonary AV fistula and nodules unchanged; pleural effusions and atelectasis improved\",\"modality\":\"CT\",\"trend_vs_prior\":\"Improved\"},{\"anatomic_sites\":[\"Liver\",\"Kidney\",\"Spine\"],\"date\":\"2022-10-08\",\"findings\":[\"Hemangioma in liver right lobe segment VII similar to prior\",\"Left renal cyst similar to prior\",\"Localized uneven sclerotic change in lumbar vertebrae similar to prior\"],\"impression\":\"Stable hemangioma and renal cyst; spinal sclerosis unchanged; chest findings to correlate with other exams\",\"modality\":\"CT\",\"trend_vs_prior\":\"Stable\"},{\"anatomic_sites\":[\"Pelvis\"],\"date\":\"2022-10-25\",\"findings\":[\"Postoperative changes after ovarian cancer surgery\",\"No abnormal soft tissue mass in pelvis\"],\"impression\":\"No pelvic recurrence; follow-up recommended\",\"modality\":\"MRI\",\"trend_vs_prior\":\"Stable\"}]},\"TIMELINE\":{\"constraints\":{\"max_events\":30,\"min_events\":3,\"must_include\":[\"first diagnostic imaging or pathology confirmation (if available)\"],\"ordering_rules\":{\"prioritize_last_event\":true}},\"events\":[{\"date\":\"2021-08-26\",\"description\":\"Primary cytoreductive surgery including radical hysterectomy, bilateral salpingo-oophorectomy, bowel resection, omentectomy, lymphadenectomy, colostomy, appendectomy\",\"event_type\":\"Surgery\",\"key_result\":\"Multiple peritoneal sites and 6/24 lymph nodes positive for carcinoma\",\"regimen_or_test\":\"Surgery\"},{\"date\":\"2021-08-26\",\"description\":\"Pathology confirmed high-grade serous carcinoma of bilateral ovaries with widespread peritoneal involvement and nodal metastases\",\"event_type\":\"Diagnosis\",\"key_result\":\"High-grade serous carcinoma, bilateral ovaries; 6/24 lymph nodes positive\",\"regimen_or_test\":\"Pathology\"},{\"date\":\"2021-09-06\",\"description\":\"Intraperitoneal chemotherapy with cisplatin 50mg\",\"event_type\":\"Chemo\",\"key_result\":\"Completed over 2021-09-06 and 2021-09-07\",\"regimen_or_test\":\"顺铂50mg腹腔化疗\"},{\"date\":\"2021-10-18\",\"description\":\"Started TP chemotherapy, planned 6 cycles\",\"event_type\":\"Chemo\",\"key_result\":\"Completed 6 cycles, last on 2022-03-22\",\"regimen_or_test\":\"TP\"},{\"date\":\"2022-03-22\",\"description\":\"Last cycle of TP chemotherapy\",\"event_type\":\"Chemo\",\"key_result\":\"Adjuvant chemotherapy completed\",\"regimen_or_test\":\"TP\"},{\"date\":\"2022-04-18\",\"description\":\"Complete blood count showing thrombocytopenia\",\"event_type\":\"Lab\",\"key_result\":\"PLT:33\",\"regimen_or_test\":\"Blood routine\"},{\"date\":\"2022-04-26\",\"description\":\"Stopped niraparib due to strong adverse reactions\",\"event_type\":\"Other\",\"key_result\":\"Maintenance paused\",\"regimen_or_test\":\"尼拉帕利\"},{\"date\":\"2022-05-23\",\"description\":\"Restarted niraparib 1# qd\",\"event_type\":\"Chemo\",\"key_result\":\"Maintenance resumed\",\"regimen_or_test\":\"尼拉帕利\"},{\"date\":\"2022-06-24\",\"description\":\"Abdominal wall hernia repair at Zhongshan Hospital\",\"event_type\":\"Surgery\",\"key_result\":\"Niraparib held for 3 weeks around surgery\",\"regimen_or_test\":\"Surgery\"},{\"date\":\"2022-09-27\",\"description\":\"CT chest/abdomen showing small bilateral pleural effusions improved; pulmonary AV fistula and nodules similar to prior\",\"event_type\":\"Imaging\",\"key_result\":\"No new malignant findings reported; abdominal details deferred\",\"regimen_or_test\":\"CT\"},{\"date\":\"2022-10-08\",\"description\":\"CT showing liver segment VII hemangioma and left renal cyst, stable\",\"event_type\":\"Imaging\",\"key_result\":\"No new findings; chest to correlate with other exams\",\"regimen_or_test\":\"CT\"},{\"date\":\"2022-10-25\",\"description\":\"Pelvic MRI after ovarian cancer surgery\",\"event_type\":\"Imaging\",\"key_result\":\"No abnormal soft tissue in pelvis; follow-up recommended\",\"regimen_or_test\":\"MR\"},{\"date\":\"2022-12-30\",\"description\":\"Zhongshan Hospital evaluation: incisional hernia, low-density lesion in right liver lobe\",\"event_type\":\"Imaging\",\"key_result\":\"Blood count and liver/kidney function generally acceptable\",\"regimen_or_test\":\"Imaging\"},{\"date\":\"2023-01-09\",\"description\":\"Recent blood routine showed platelet count 34 (year not fully specified)\",\"event_type\":\"Lab\",\"key_result\":\"PLT:34 (interpreted from 'PLT:342022.5.23起恢复', year unclear)\",\"regimen_or_test\":\"Blood routine\"}]},\"TOXICITIES\":[{\"attribution\":\"Probable\",\"dose_modification\":\"Yes\",\"onset_date\":\"2022-04-18\",\"outcome\":\"Resolved\",\"related_line\":\"1L\",\"related_regimen\":\"尼拉帕利\",\"severity\":\"Severe\",\"toxicity\":\"Strong adverse reaction to niraparib with thrombocytopenia (PLT 33)\"}]}", "final_output": "Final Assessment:\nPost–primary surgery, adjuvant platinum, now on first‑line PARP maintenance with HRD‑positive disease, ECOG 1, no radiologic recurrence. Major concern is recurrent severe thrombocytopenia temporally related to maintenance. Missing: up‑to‑date CBC, renal/hepatic function, CA‑125, BRCA1/2 status, detailed current PARP dose/schedule, and full report of the “low‑density liver lesion.”\n\nCore Treatment Strategy:\n- Continue first‑line PARP maintenance in principle, but urgently reassess dose/intensity given recurrent severe thrombocytopenia. [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8; @pubmed | 40687421]  \n- Obtain immediate CBC, coagulation, renal/hepatic function, CA‑125, and characterize liver lesion with dedicated imaging before firm long‑term decisions.  \n- Schedule structured surveillance: symptom review, exam, CA‑125, and cross‑sectional imaging every 3–6 months while on maintenance. [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 10]  \n\nChange Triggers:\n- If platelets remain <50×10⁹/L or other grade ≥3 cytopenias, hold/modify or discontinue PARP and involve hematology. [@pubmed | 40687421]  \n- If imaging or CA‑125 indicates first recurrence, re‑stage fully and pivot to recurrence strategy with platinum‑based systemic therapy consideration. [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]\n\n---\n## References\n\n### Guidelines\n\n[@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\n  Document: esmo_cpg_epithelialovarian_2023__v00000000, Page 8\n  Content: MCBS v1.1 score: 4; ESMO Scale for Clinical Actionabil-\nity...\n\n[@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 10]\n  Document: esgo_esmo_esp_consensus_ovariancancer_2024__v00000000, Page 10\n  Content: platinum-based ChT followed by niraparib or rucaparib if\nin...\n\n[@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]\n  Document: nccn_ovariancancer_v3_2025__v00000000, Page 15\n  Content: and/or disease status.\nii Ancillary Palliative Surgical...\n\n### Literature\n\n[@pubmed | 40687421]\n  PMID: 40687421 | Front Oncol | 2025-01-01\n  Title: Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review.\n  DOI: 10.3389/fonc.2025.1542646\n\n### Clinical Trials\n\n### Clinical Reports\n", "initial_ops": {"chair": "(Single agent mode)"}, "merged_summary": "(Chair-SA(K): Knowledge only mode)", "final_round_ops": {}, "interaction_log": {}, "agent_logs": {"chair": [{"role": "chair", "user_message": "\nAs the MDT chair for gynecologic oncology, you are seeing the patient at OUTPATIENT TIME: 2023-01-09 09:23:13.113000.\nBased on the case information and knowledge evidence provided in your system prompt, determine the CURRENT best management plan for this visit.\n\nNOTE: You only have access to Knowledge (guidelines + literature). No patient-specific clinical reports are available.\n\nSTRICT RULES:\n- Any statement derived from guideline or PubMed must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\n- If key patient data is missing, clearly state what additional tests/reports are needed.\n- Be conservative in recommendations when lacking specific patient evidence.\n\n# Response Format\nFinal Assessment:\n<1–3 sentences: summarize case, current status, and key uncertainties/missing data>\n\nCore Treatment Strategy:\n- < ≤20 words concrete decision or recommended next step >\n- < ≤20 words concrete decision or recommended next step >\n- < ≤20 words concrete decision or recommended next step >\n\nChange Triggers:\n- < ≤20 words \"if X, then adjust management from A to B\" >\n- < ≤20 words \"if X, then adjust management from A to B\" >\n", "assistant_reply": "Final Assessment:\nPost–primary surgery, adjuvant platinum, now on first‑line PARP maintenance with HRD‑positive disease, ECOG 1, no radiologic recurrence. Major concern is recurrent severe thrombocytopenia temporally related to maintenance. Missing: up‑to‑date CBC, renal/hepatic function, CA‑125, BRCA1/2 status, detailed current PARP dose/schedule, and full report of the “low‑density liver lesion.”\n\nCore Treatment Strategy:\n- Continue first‑line PARP maintenance in principle, but urgently reassess dose/intensity given recurrent severe thrombocytopenia. [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8; @pubmed | 40687421]  \n- Obtain immediate CBC, coagulation, renal/hepatic function, CA‑125, and characterize liver lesion with dedicated imaging before firm long‑term decisions.  \n- Schedule structured surveillance: symptom review, exam, CA‑125, and cross‑sectional imaging every 3–6 months while on maintenance. [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 10]  \n\nChange Triggers:\n- If platelets remain <50×10⁹/L or other grade ≥3 cytopenias, hold/modify or discontinue PARP and involve hematology. [@pubmed | 40687421]  \n- If imaging or CA‑125 indicates first recurrence, re‑stage fully and pivot to recurrence strategy with platinum‑based systemic therapy consideration. [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]", "timestamp": "2026-01-22T18:32:56.939934"}]}, "trace_events": [{"ts": "2026-01-22T18:32:22.934136", "event": "pipeline_start", "payload": {"mode": "chair_sa_k", "visit_time": "2023-01-09 09:23:13.113000"}}, {"ts": "2026-01-22T18:32:22.934673", "event": "case_fingerprint", "payload": {"case_fingerprint": "fa2f34f1e565"}}, {"ts": "2026-01-22T18:32:23.061279", "event": "rag_key_facts", "payload": {"facts": "DIAGNOSIS: primary=Ovarian cancer; histology=High-grade serous carcinoma; components=Adenocarcinoma;High-grade serous carcinoma\nPATHOLOGY: Adenocarcinoma consistent with high-grade serous carcinoma\nPLATINUM: status=Unknown; pfi_days=Unknown\nGENETICS: HRD=Positive; BRCA1=Unknown; BRCA2=Unknown\nBIOMARKERS: CA125=Unknown; AFP=Unknown; TMB=Unknown; MSI=Unknown; PDL1_CPS=Unknown"}}, {"ts": "2026-01-22T18:32:45.139357", "event": "rag_query", "payload": {"query": "HRD-positive high-grade serous ovarian carcinoma, platinum-sensitive, with prior extensive peritoneal and nodal metastases; on niraparib maintenance complicated by severe thrombocytopenia but otherwise acceptable organ function; histology: High-grade serous carcinoma"}}, {"ts": "2026-01-22T18:32:45.139369", "event": "rag_hits_merged", "payload": {"n": 10}}], "trace_mermaid": "flowchart TD\n  A[Load Case + Fingerprint] --> B[Load Reports]\n  B --> C[Report Selection per Role]\n  C --> D[Guideline+PubMed RAG]\n  D --> E[Init Specialist Agents]\n  E --> F[MDT Discussion Engine]\n  F --> G[Trial Matching]\n  G --> H[Final Chair Output]\n  H --> I[Save Logs]\n"}
